Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Antagonises central dopamine D2 receptors and also interacts with other monoamine receptors, reducing dopaminergic signalling associated with psychosis. Low-dose and depot formulations have different clinical uses and duration.
Indications / reported uses
Treatment of schizophrenia and other psychotic disorders with oral or depot formulations in countries where authorised
Low-dose oral flupentixol has been used for depressive or anxiety symptoms in some jurisdictions, but these indications are not universal and should be assigned only to the specific authorised product
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Flupentixol PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Flupentixol Permitted Daily Exposure (PDE) report (the Flupentixol PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Flupentixol Occupational Exposure Limit (OEL) report (the Flupentixol OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.